返回新闻列表Back to News
佰睿壹生物作为官方合作伙伴亮相第17届 World ADC 大会，全方位展示 DAR1 ADC/AXC 与双载荷 ADC 平台及管线突破
Bio-reinnovation Participates in 17th World ADC San Diego as Official Partner, Showcasing Breakthroughs in DAR1 ADC/AXC and Dual-Payload ADC Platforms and Pipeline
（美国圣地亚哥，2026年10月13日） —— 佰睿壹生物作为大会官方合作伙伴（Official Partner），受邀出席于美国圣地亚哥举办的第17届全球抗体偶联药物峰会（17th Annual World ADC San Diego 2026）。会议期间，公司首席执行官（CEO）吴丽丽博士 在核心的发现化学（Discovery Chemistry）专场发表主题演讲，并受邀参与专场总结圆桌讨论。
一、CEO 主题演讲：纯化学偶联路径重塑 ADC 设计灵活性与开发效率
吴丽丽博士发表了题为《BioReinnovation's Platform Accelerates Innovation in DAR1 ADC/AXC and Dual-Payload ADCs — Pure Chemo Approach: Redefining ADC Design Flexibility And Efficiency》的主题报告，核心突破点包括：
• 四大底层技术矩阵协同：系统阐释了以 MCLICK™（定点偶联）、HILT™（亲水性连接子-载荷）、UDAC™（超低 DAR 偶联）及 DPAC™（双载荷组装）为核心的化学驱动创新体系。该纯化学策略无需复杂的抗体工程改造或酶催化，即可实现“即插即用（Plug-and-Play）”的精准偶联。
• 超低 DAR1 ADC/AXC 差异化设计空间（“DAR1 Beats More”）：展示了高精度 DAR1 技术在新型抗体偶联物（ADC、AOC、APC 等）中的应用潜力，在同等或更低给药剂量下展现出超越传统高 DAR 偶联物的抑瘤活性与大幅拓宽的安全窗口。
• 双载荷比例精准调控与耐药破局：揭示了不同作用机制载荷（如 TOP1i+MTI、TOP1i+DDRi 等）的配比对协同效应的关键影响，验证了双载荷 ADC 在后线及单载荷 ADC 获得性耐药再挑战（Rechallenge）场景下的显著优势。
• 研发管线与融资里程碑：宣布公司已于 2026 年完成 1000 万美元 Pre-A 轮融资；目前共推进 6 条双载荷 ADC 研发管线，其中 5 个临床前候选化合物（PCC）已确定，并同步开展双抗双载荷及双抗三载荷 ADC 的早期探索，计划于 2027 年启动首个 I 期临床试验。
二、受邀参与圆桌讨论，携手全球伙伴共拓合作
演讲结束后，吴丽丽博士受邀参与题为《Summary Panel Discussion: What is Showing the Most Promise & What Still Needs to be Proven in ADC Chemistry & Mechanistic Innovation?》的专场总结圆桌论坛，与国际同行深入探讨下一代 ADC 化学与机制创新的临床转化方向。依托已建立的 CRDMO 战略合作及多元化的商业模式（技术平台授权、管线产品授权与共同开发），佰睿壹生物将持续赋能全球合作伙伴加速下一代创新偶联药物的开发。（注：本次大会期间发布的最新双载荷 ADC 学术壁报已同步收录于新闻中心“出版物及IP”专栏。） (San Diego, USA, October 13, 2026) — Bio-reinnovation participated as an Official Partner in the 17th Annual World ADC San Diego 2026 Summit. During the Discovery Chemistry track, Co-Founder & CEO Dr. Lili Wu delivered a keynote presentation and joined the track's Summary Panel Discussion.
1. CEO Keynote Presentation: Redefining ADC Design Flexibility and Efficiency via a Pure Chemical Approach
In her presentation titled “BioReinnovation's Platform Accelerates Innovation in DAR1 ADC/AXC and Dual-Payload ADCs — Pure Chemo Approach: Redefining ADC Design Flexibility And Efficiency”, Dr. Lili Wu highlighted several key technological and corporate breakthroughs:
• Chemistry-Driven Platform Matrix: Showcased the synergy across Bio-reinnovation's four core platforms—MCLICK™ (precision site-specific conjugation), HILT™ (hydrophilic linker-payload technology), UDAC™ (ultra-low DAR conjugates), and DPAC™ (dual-payload assembly). Replacing complex protein engineering and enzymatic processes, this pure chemical approach enables plug-and-play ADC/AXC design with exceptional DAR selectivity.
• “DAR1 Beats More” — Differentiated Design Space in Ultra-Low DAR1 ADC/AXCs: Demonstrated how highly homogeneous DAR1 bioconjugates (including ADCs, AOCs, and APCs) achieve superior in vivo tumor inhibition and a significantly broader therapeutic window compared to conventional higher-DAR counterparts.
• Rational Dual-Payload Synergy & Overcoming Resistance: Illustrated how precise payload ratio optimization drives potent mechanistic synergy (e.g., TOP1i+MTI, TOP1i+DDRi) and enables effective tumor control in post-line rechallenge models resistant to single-payload ADCs.
• Pipeline & Corporate Milestones: Announced the completion of a $10 million Pre-A financing round in 2026 and the advancement of 6 preclinical dual-payload ADC programs, with 5 Preclinical Candidates (PCCs) ready and the first Phase 1 clinical study planned for 2027.
2. Summary Panel Discussion & Global Partnering Momentum
Following her talk, Dr. Lili Wu joined industry leaders as a panelist in the “Summary Panel Discussion: What is Showing the Most Promise & What Still Needs to be Proven in ADC Chemistry & Mechanistic Innovation?”. Through flexible partnership models—including technology licensing, product licensing, and co-development—Bio-reinnovation continues to expand its global collaboration network to accelerate the translation of next-generation bioconjugate therapeutics. (Note: The latest dual-payload ADC scientific poster presented at the conference is available in the Publications & IP section.)
一、CEO 主题演讲：纯化学偶联路径重塑 ADC 设计灵活性与开发效率
吴丽丽博士发表了题为《BioReinnovation's Platform Accelerates Innovation in DAR1 ADC/AXC and Dual-Payload ADCs — Pure Chemo Approach: Redefining ADC Design Flexibility And Efficiency》的主题报告，核心突破点包括：
• 四大底层技术矩阵协同：系统阐释了以 MCLICK™（定点偶联）、HILT™（亲水性连接子-载荷）、UDAC™（超低 DAR 偶联）及 DPAC™（双载荷组装）为核心的化学驱动创新体系。该纯化学策略无需复杂的抗体工程改造或酶催化，即可实现“即插即用（Plug-and-Play）”的精准偶联。
• 超低 DAR1 ADC/AXC 差异化设计空间（“DAR1 Beats More”）：展示了高精度 DAR1 技术在新型抗体偶联物（ADC、AOC、APC 等）中的应用潜力，在同等或更低给药剂量下展现出超越传统高 DAR 偶联物的抑瘤活性与大幅拓宽的安全窗口。
• 双载荷比例精准调控与耐药破局：揭示了不同作用机制载荷（如 TOP1i+MTI、TOP1i+DDRi 等）的配比对协同效应的关键影响，验证了双载荷 ADC 在后线及单载荷 ADC 获得性耐药再挑战（Rechallenge）场景下的显著优势。
• 研发管线与融资里程碑：宣布公司已于 2026 年完成 1000 万美元 Pre-A 轮融资；目前共推进 6 条双载荷 ADC 研发管线，其中 5 个临床前候选化合物（PCC）已确定，并同步开展双抗双载荷及双抗三载荷 ADC 的早期探索，计划于 2027 年启动首个 I 期临床试验。
二、受邀参与圆桌讨论，携手全球伙伴共拓合作
演讲结束后，吴丽丽博士受邀参与题为《Summary Panel Discussion: What is Showing the Most Promise & What Still Needs to be Proven in ADC Chemistry & Mechanistic Innovation?》的专场总结圆桌论坛，与国际同行深入探讨下一代 ADC 化学与机制创新的临床转化方向。依托已建立的 CRDMO 战略合作及多元化的商业模式（技术平台授权、管线产品授权与共同开发），佰睿壹生物将持续赋能全球合作伙伴加速下一代创新偶联药物的开发。（注：本次大会期间发布的最新双载荷 ADC 学术壁报已同步收录于新闻中心“出版物及IP”专栏。） (San Diego, USA, October 13, 2026) — Bio-reinnovation participated as an Official Partner in the 17th Annual World ADC San Diego 2026 Summit. During the Discovery Chemistry track, Co-Founder & CEO Dr. Lili Wu delivered a keynote presentation and joined the track's Summary Panel Discussion.
1. CEO Keynote Presentation: Redefining ADC Design Flexibility and Efficiency via a Pure Chemical Approach
In her presentation titled “BioReinnovation's Platform Accelerates Innovation in DAR1 ADC/AXC and Dual-Payload ADCs — Pure Chemo Approach: Redefining ADC Design Flexibility And Efficiency”, Dr. Lili Wu highlighted several key technological and corporate breakthroughs:
• Chemistry-Driven Platform Matrix: Showcased the synergy across Bio-reinnovation's four core platforms—MCLICK™ (precision site-specific conjugation), HILT™ (hydrophilic linker-payload technology), UDAC™ (ultra-low DAR conjugates), and DPAC™ (dual-payload assembly). Replacing complex protein engineering and enzymatic processes, this pure chemical approach enables plug-and-play ADC/AXC design with exceptional DAR selectivity.
• “DAR1 Beats More” — Differentiated Design Space in Ultra-Low DAR1 ADC/AXCs: Demonstrated how highly homogeneous DAR1 bioconjugates (including ADCs, AOCs, and APCs) achieve superior in vivo tumor inhibition and a significantly broader therapeutic window compared to conventional higher-DAR counterparts.
• Rational Dual-Payload Synergy & Overcoming Resistance: Illustrated how precise payload ratio optimization drives potent mechanistic synergy (e.g., TOP1i+MTI, TOP1i+DDRi) and enables effective tumor control in post-line rechallenge models resistant to single-payload ADCs.
• Pipeline & Corporate Milestones: Announced the completion of a $10 million Pre-A financing round in 2026 and the advancement of 6 preclinical dual-payload ADC programs, with 5 Preclinical Candidates (PCCs) ready and the first Phase 1 clinical study planned for 2027.
2. Summary Panel Discussion & Global Partnering Momentum
Following her talk, Dr. Lili Wu joined industry leaders as a panelist in the “Summary Panel Discussion: What is Showing the Most Promise & What Still Needs to be Proven in ADC Chemistry & Mechanistic Innovation?”. Through flexible partnership models—including technology licensing, product licensing, and co-development—Bio-reinnovation continues to expand its global collaboration network to accelerate the translation of next-generation bioconjugate therapeutics. (Note: The latest dual-payload ADC scientific poster presented at the conference is available in the Publications & IP section.)
佰睿壹生物联合创始人兼CEO 吴丽丽博士发表主题演讲，介绍公司平台与管线进展
Dr. Lili Wu, Co-Founder & CEO of Bio-reinnovation, delivering keynote presentation on corporate and pipeline advances
吴丽丽博士受邀参与 ADC 化学与机制创新总结圆桌讨论（Summary Panel Discussion）
Dr. Lili Wu participating in the Summary Panel Discussion on ADC Chemistry & Mechanistic Innovation
佰睿壹生物作为官方合作伙伴（Partner）亮相第17届 World ADC San Diego 大会
Bio-reinnovation as an Official Partner at the 17th Annual World ADC San Diego 2026